FDA Approves Takeda’s Orzeyful, First Medicine to Target the Root Cause of Narcolepsy Type 1

Company: Takeda · Event Type: FDA Approval · Product: Orzeyful (oveporexton / TAK-861) · Mechanism: Oral Orexin Receptor 2 Agonist · Indication: Narcolepsy Type 1 in Adults · Approval Date: August 5, 2026 Summary The FDA approved Takeda’s Orzeyful (oveporexton), an oral orexin receptor 2…